Thu, January 6, 2022

Matthew Harrison Downgraded (AVIR) to Sell and Decreased Target to $7 on, Jan 6th, 2022

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. l-and-decreased-target-to-7-on-jan-6th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Matthew Harrison of Morgan Stanley, Downgraded "Atea Pharmaceuticals, Inc." (AVIR) to Sell and Decreased Target from $14 to $7 on, Jan 6th, 2022.

Matthew has made no other calls on AVIR in the last 4 months.



There are 2 other peers that have a rating on AVIR. Out of the 2 peers that are also analyzing AVIR, all agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Roanna Ruiz of "SVB Leerink" Downgraded from Buy to Hold and Held Target at $11 on, Thursday, November 18th, 2021
  • Eric Joseph of "JP Morgan" Downgraded from Buy to Hold and Decreased Target to $16 on, Wednesday, October 20th, 2021